Stockreport

Intercept's Pain Is Galectin's Gain: Clinical Outcomes In NASH Are Crucial [Seeking Alpha]

Galectin Therapeutics Inc.  (GALT) 
Last galectin therapeutics inc. earnings: 11/12 08:00 am Check Earnings Report
PDF SummaryGalectin commences its adaptive phase 3 trial.Genfit flunks its phase 3 trial.FDA rejects Intercept’s NDA for NASH fibrosis.Galectin’s phase 3 trial is primed for [Read more]